Diagnostic Radioisotopes Global Market Report 2025
상품코드:1704114
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 200 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
진단용 방사성동위원소 시장 규모는 향후 수년간 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 9.7%의 연평균 복합 성장률(CAGR)로 88억 3,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 새로운 방사성동위원소 제조법, 임상 적용 확대, 환자 중심 치료 및 안전, 현장 진료 영상 진단, 환경 지속가능성 및 그린 케미스트리에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 하이브리드 이미징 기술, 세라믹, 분자 이미징 기술, 사이클로트론 또는 제너레이터 사용, 안전 및 방사선 보호 등이 있습니다.
암에 대한 부담 증가가 진단용 방사성동위원소 시장 확대를 견인할 것으로 예상됩니다. 암은 주변 조직을 손상시키는 비정상적인 세포의 무질서한 분열을 특징으로 하는 질병입니다. 암의 유병률 증가는 흡연, 비만, 운동 부족과 같은 생활습관 선택, 발암물질 노출, 유전적 요인, 환경적 영향 등 다양한 요인에 기인합니다. 방사성동위원소는 정확한 진단을 제공하고, 표적 치료를 가능하게 하며, 암의 진행과 치료에 대한 반응을 효과적으로 모니터링하는 것을 용이하게 함으로써 암 관리에 중요한 역할을 하고 있습니다. 예를 들어 2024년 5월 미국 국립암연구소(National Cancer Institute)는 2040년까지 전 세계 연간 신규 암 환자 수가 2,990만 명에 달하고 암으로 인한 사망자 수가 1,530만 명에 달할 것으로 예측했습니다. 이에 따라 암 부담 증가가 진단용 방사성동위원소 시장의 성장을 촉진하고 있습니다.
진단용 방사성동위원소 시장의 주요 기업은 진단 정확도 향상, 환자 결과 개선, 헬스케어에서 핵의학의 적용 확대를 위해 방사성 의약품 기술의 발전에 주력하고 있습니다. 첨단 방사성 의약품 기술에는 핵의학에서 정확한 이미징과 표적 치료를 위한 혁신적인 화합물 및 기술 개발이 포함됩니다. 예를 들어 이탈리아의 영상 진단 회사인 브라코 그룹은 2022년 3월 차세대 치료용 방사성 의약품 기술 개발을 전문으로 하는 자회사 블루어스 테라퓨틱스(Blue Earth Therapeutics)를 설립하고, 초기에는 전립선암을 타겟으로 하고 다른 암 분야로 확대할 계획입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, Covid 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 진단용 방사성동위원소 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 진단용 방사성동위원소 시장 : 성장률 분석
세계의 진단용 방사성동위원소 시장 실적 : 규모와 성장, 2019-2024
세계의 진단용 방사성동위원소 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 진단용 방사성동위원소 TAM(Total Addressable Market)
제6장 시장 세분화
세계의 진단용 방사성동위원소 시장 : 방사성 동위 원소별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
테크네튬 99m
탈륨 201
갈륨 67
요오드 123
FluoroDeoxyGlucose(FDG)
루비듐 82
기타 방사성 동위 원소
세계의 진단용 방사성동위원소 시장 : 영상 진단법별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
단일 광자 방출 컴퓨터 단층촬영(SPECT)
양전자 방출 단층촬영(PET)
베타선 방사체
세계의 진단용 방사성동위원소 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
종양학
심장병학
기타 용도
세계의 진단용 방사성동위원소 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
진단 센터
학술연구기관
기타 최종사용자
세계의 진단용 방사성동위원소 시장, 테크네튬 99m의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
진단 영상
심장 영상
종양 영상 진단
뼈스캔
신장 스캔
세계의 진단용 방사성동위원소 시장, 탈륨 201의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
심장 영상
심근 혈류 이미징
스트레스 테스트
세계의 진단용 방사성동위원소 시장, 갈륨 67의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
종양 영상 진단(림프종, 종양)
염증성 질환 영상 진단
감염 영상 진단
세계의 진단용 방사성동위원소 시장, 요오드 123의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
갑상선 영상 검사
신경학적 영상 검사(파킨슨병)
심장 영상
세계의 진단용 방사성동위원소 시장, FluoroDeoxyGlucose(FDG)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
양전자 방출 단층촬영(PET) 영상
암 진단과 스테이징
신경 영상
심장 영상
세계의 진단용 방사성동위원소 시장, 루비듐 82의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
심장 PET 영상
심근 혈류 이미징
관상동맥 질환 진단
세계의 진단용 방사성동위원소 시장, 기타 방사성 동위 원소의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
스트론튬 89(골통완화)
요오드 131(갑상선암 치료)
사마륨 153(골통완화)
이트륨 90(암치료)
제7장 지역별·국가별 분석
세계의 진단용 방사성동위원소 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 진단용 방사성동위원소 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
진단용 방사성동위원소 시장 : 경쟁 구도
진단용 방사성동위원소 시장 : 기업 개요
Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
Sumitomo Heavy Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
Lantheus Holdings Overview, Products and Services, Strategy and Financial Analysis
Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Clarity Pharmaceuticals
Bracco Diagnostic Inc.
Ion Beam Applications S.A.
Nordion Inc.
Eckert & Ziegler AG
NorthStar Medical Radioisotopes LLC
NTP Radioisotopes SOC Ltd
Global Medical Solutions Ltd.
Isotopia Molecular Imaging Ltd.
Cyclopharm Limited
Trasis NV
Orano Med LLC
ARTMS Inc.
Radiomedix Inc.
Coqu RadioPharmaceuticals Corp.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
진단용 방사성동위원소 시장 2029 : 새로운 기회를 제공하는 국가
진단용 방사성동위원소 시장 2029 : 새로운 기회를 제공하는 부문
진단용 방사성동위원소 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁의 전략
제36장 부록
KSA
영문 목차
영문목차
Diagnostic radioisotopes are radioactive isotopes employed in nuclear medicine for diagnosing and monitoring diverse medical conditions. They rely on their radioactive decay characteristics to emit radiation, detected by specialized imaging tools, enabling healthcare providers to acquire detailed internal body structure images and evaluate their function.
The primary diagnostic radioisotopes include technetium-99m, thallium-201, gallium-67, iodine-123, fluorodeoxyglucose (FDG), rubidium-82, and others. Technetium-99m is extensively used in medical imaging due to its advantageous nuclear properties and wide accessibility. Imaging techniques include single photon emission computed tomography (SPECT), positron emission tomography (PET), and beta emitters, employed across various fields such as oncology and cardiology.
The diagnostic radioisotopes research report is one of a series of new reports from The Business Research Company that provides diagnostic radioisotopes market statistics, including the diagnostic radioisotopes industry's global market size, regional shares, competitors with a diagnostic radioisotopes market share, detailed diagnostic radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic radioisotopes industry. This diagnostic radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The diagnostic radioisotopes market size has grown rapidly in recent years. It will grow from $5.54 billion in 2024 to $6.1 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to the discovery of radioactivity, the introduction of technetium-99m, clinical applications and research, cold war era and nuclear research, and emergence of positron emission tomography.
The diagnostic radioisotopes market size is expected to see strong growth in the next few years. It will grow to $8.83 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to emerging radioisotope production methods, expanded clinical applications, patient-centered care and safety, point-of-care imaging and environmental sustainability and green chemistry. Major trends in the forecast period include hybrid imaging techniques, theranostics, molecular imaging techniques, the use of cyclotrons or generators, and safety and radiation protection.
The growing burden of cancer is expected to drive the expansion of the diagnostic radioisotopes market. Cancer is a disease characterized by the uncontrolled division of abnormal cells that damage surrounding tissue. The increasing prevalence of cancer is attributed to various factors, including lifestyle choices such as smoking, obesity, lack of physical activity, exposure to carcinogens, genetic factors, and environmental influences. Radioisotopes play a crucial role in cancer management by providing accurate diagnosis, enabling targeted treatments, and facilitating effective monitoring of cancer progression or response to therapy. For example, in May 2024, the National Cancer Institute, a US-based government agency focused on cancer research and training, projected that by 2040, the global number of new cancer cases per year will reach 29.9 million, with 15.3 million cancer-related deaths. As a result, the rising burden of cancer is driving the growth of the diagnostic radioisotopes market.
Key players in the diagnostic radioisotopes market are focused on advancing radiopharmaceutical technology to enhance diagnostic accuracy, improve patient outcomes, and expand the applications of nuclear medicine in healthcare. Advanced radiopharmaceutical technology involves the development of innovative compounds and techniques for precise imaging and targeted therapy in nuclear medicine. For example, Bracco Group, an Italy-based diagnostic imaging company, launched Blue Earth Therapeutics in March 2022, a subsidiary dedicated to advancing next-generation therapeutic radiopharmaceutical technology, initially targeting prostate cancer with plans for further expansion into other oncology areas.
In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS to strengthen its supply chain and manufacturing capabilities. This acquisition aims to leverage ARTMS' expertise in cyclotron-based isotope production to enhance market position and meet the growing demand for diagnostic and therapeutic isotopes. ARTMS, headquartered in Canada, specializes in radioisotope technology and is a leading provider of diagnostic radioisotopes.
Major companies operating in the diagnostic radioisotopes market are Cardinal Health Inc., Sumitomo Heavy Industries Ltd., BWX Technologies Inc., Lantheus Holdings, Curium Pharma, Clarity Pharmaceuticals, Bracco Diagnostic Inc., Ion Beam Applications S.A., Nordion Inc., Eckert & Ziegler AG, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Global Medical Solutions Ltd., Isotopia Molecular Imaging Ltd., Cyclopharm Limited, Trasis NV, Orano Med LLC, ARTMS Inc., Radiomedix Inc., Coqu RadioPharmaceuticals Corp., IsoTherapeutics Group LLC
North America was the largest region in the diagnostic radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diagnostic radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the diagnostic radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The diagnostic radioisotopes market consists of revenues earned by entities by providing services such as radiopharmacy services, imaging services, radioisotope production and supply, diagnostic procedures, and theranostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The diagnostic radioisotopes market also includes sales of products including Indium-111, Xenon-133, Molybdenum-99, and Phosphorus-32. Values in this market are 'factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Diagnostic Radioisotopes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on diagnostic radioisotopes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for diagnostic radioisotopes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diagnostic radioisotopes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Radioisotope: Technetium-99m; Thallium-201; Gallium-67; Iodine-123; FluoroDeoxyGlucose (FDG); Rubidium-82; Other Radioisotopes
2) By Imaging Modality: Single Photon Emission Computed Tomography (SPECT); Positron Emission Tomography (PET); Beta Emitters
3) By Application: Oncology; Cardiology; Other Applications
4) By End User: Hospitals; Specialty Clinics; Diagnostic Centers; Academic And Research Institutes; Other End Users
Subsegments:
1) By Technetium-99m: Diagnostic Imaging; Cardiac Imaging; Oncology Imaging; Bone Scans; Renal Scans
2) By Thallium-201: Cardiac Imaging; Myocardial Perfusion Imaging; Stress Tests
3. Diagnostic Radioisotopes market Trends And Strategies
4. Diagnostic Radioisotopes market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Diagnostic Radioisotopes Growth Analysis And Strategic Analysis Framework
5.1. Global Diagnostic Radioisotopes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Diagnostic Radioisotopes market Growth Rate Analysis
5.4. Global Diagnostic Radioisotopes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Diagnostic Radioisotopes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Diagnostic Radioisotopes Total Addressable Market (TAM)
6. Diagnostic Radioisotopes market Segmentation
6.1. Global Diagnostic Radioisotopes market, Segmentation By Radioisotope, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Technetium-99m
Thallium-201
Gallium-67
Iodine-123
FluoroDeoxyGlucose (FDG)
Rubidium-82
Other Radioisotopes
6.2. Global Diagnostic Radioisotopes market, Segmentation By Imaging Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single Photon Emission Computed Tomography (SPECT)
Positron Emission Tomography (PET)
Beta Emitters
6.3. Global Diagnostic Radioisotopes market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Cardiology
Other Applications
6.4. Global Diagnostic Radioisotopes market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Diagnostic Centers
Academic And Research Institutes
Other End Users
6.5. Global Diagnostic Radioisotopes Market, Sub-Segmentation Of Technetium-99m, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostic Imaging
Cardiac Imaging
Oncology Imaging
Bone Scans
Renal Scans
6.6. Global Diagnostic Radioisotopes Market, Sub-Segmentation Of Thallium-201, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardiac Imaging
Myocardial Perfusion Imaging
Stress Tests
6.7. Global Diagnostic Radioisotopes Market, Sub-Segmentation Of Gallium-67, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology Imaging (Lymphoma, Tumors)
Inflammatory Disease Imaging
Infection Imaging
6.8. Global Diagnostic Radioisotopes Market, Sub-Segmentation Of Iodine-123, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Thyroid Imaging
Neurological Imaging (Parkinson's Disease)
Cardiac Imaging
6.9. Global Diagnostic Radioisotopes Market, Sub-Segmentation Of FluoroDeoxyGlucose (FDG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Positron Emission Tomography (PET) Imaging
Cancer Diagnosis And Staging
Neurological Imaging
Cardiac Imaging
6.10. Global Diagnostic Radioisotopes Market, Sub-Segmentation Of Rubidium-82, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardiac PET Imaging
Myocardial Perfusion Imaging
Coronary Artery Disease Diagnosis
6.11. Global Diagnostic Radioisotopes Market, Sub-Segmentation Of Other Radioisotopes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Strontium-89 (Bone Pain Palliation)
Iodine-131 (Thyroid Cancer Treatment)
Samarium-153 (Bone Pain Palliation)
Yttrium-90 (Cancer Treatment)
7. Diagnostic Radioisotopes market Regional And Country Analysis
7.1. Global Diagnostic Radioisotopes market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Diagnostic Radioisotopes market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
